Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

NCT06401577 · View on ClinicalTrials.gov ↗

Study Summary

The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.

Conditions Studied

Interventions

  • DEVICE Dexcom Continuous Glucose Monitor (CGM)

Study Locations (13)

California

  • University of Southern California — Los Angeles
  • Cedars-Sinai Medical Center — Los Angeles
  • Stanford University — Stanford

Florida

  • University of Florida — Gainesville
  • AdventHealth — Orlando

Illinois

  • Northwestern University — Chicago
  • University of Illinois at Chicago — Chicago

Indiana

  • Indiana University — Indianapolis

Maryland

  • Johns Hopkins University — Baltimore

Minnesota

  • University of Minnesota — Minneapolis

Ohio

  • Ohio State University — Columbus

Pennsylvania

  • University of Pittsburgh — Pittsburgh

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2024-10-16
Est. Completion 2027-03-31

Sponsor

Milton S. Hershey Medical Center

277 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06401577

The ClinicalTrials.gov registry entry for NCT06401577 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 277 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention — of which Dexcom Continuous Glucose Monitor (CGM) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06401577 reports 13 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06401577 about?

NCT06401577 is a clinical study titled "Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics". The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophy...

What is the current status of trial NCT06401577?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2024-10-16. Estimated completion is 2027-03-31.

What conditions does trial NCT06401577 study?

This clinical trial studies the following conditions: Acute Pancreatitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06401577?

The interventions under investigation include: Dexcom Continuous Glucose Monitor (CGM) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06401577?

This trial is sponsored by Milton S. Hershey Medical Center, which has 277 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06401577 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial